The ACTC has selected two of Eisai’s investigational compounds for evaluation in upcoming clinical studies starting early in 2020. These studies will target primary and secondary prevention of Alzheimer’s disease (AD) and will be conducted with funding from various sources including the United States National Institute on Ageing (NIA).

As an NIA-funded clinical trial network, the ACTC has 35 primary study sites across the United States and aims to accelerate and expand studies for therapies in AD and related dementias across the spectrum from pre-symptomatic to more severe stages of the disease.



Post Navigation